These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 1535193)

  • 1. In vitro inhibition of c-myc transcription by mithramycin.
    Hardenbol P; Van Dyke MW
    Biochem Biophys Res Commun; 1992 Jun; 185(2):553-8. PubMed ID: 1535193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mithramycin blocks transcriptional initiation of the c-myc P1 and P2 promoters.
    Snyder RC; Ray R; Blume S; Miller DM
    Biochemistry; 1991 Apr; 30(17):4290-7. PubMed ID: 1827033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mithramycin selectively inhibits the transcriptional activity of a transfected human c-myc gene.
    Ray R; Thomas S; Miller DM
    Am J Med Sci; 1990 Oct; 300(4):203-8. PubMed ID: 2147360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The G-C specific DNA binding drug, mithramycin, selectively inhibits transcription of the C-MYC and C-HA-RAS genes in regenerating liver.
    Campbell VW; Davin D; Thomas S; Jones D; Roesel J; Tran-Patterson R; Mayfield CA; Rodu B; Miller DM; Hiramoto RA
    Am J Med Sci; 1994 Mar; 307(3):167-72. PubMed ID: 8160706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mithramycin selectively inhibits transcription of G-C containing DNA.
    Miller DM; Polansky DA; Thomas SD; Ray R; Campbell VW; Sanchez J; Koller CA
    Am J Med Sci; 1987 Nov; 294(5):388-94. PubMed ID: 2962490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target.
    Remsing LL; Bahadori HR; Carbone GM; McGuffie EM; Catapano CV; Rohr J
    Biochemistry; 2003 Jul; 42(27):8313-24. PubMed ID: 12846580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
    Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
    Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of beta-galactosidase under the control of the human c-myc promoter in transgenic mice is inhibited by mithramycin.
    Jones DE; Cui DM; Miller DM
    Oncogene; 1995 Jun; 10(12):2323-30. PubMed ID: 7784080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo.
    Blume SW; Snyder RC; Ray R; Thomas S; Koller CA; Miller DM
    J Clin Invest; 1991 Nov; 88(5):1613-21. PubMed ID: 1834700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of p53-mediated transcriptional responses by mithramycin A.
    Koutsodontis G; Kardassis D
    Oncogene; 2004 Dec; 23(57):9190-200. PubMed ID: 15489892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mithramycin blocks protein binding and function of the SV40 early promoter.
    Ray R; Snyder RC; Thomas S; Koller CA; Miller DM
    J Clin Invest; 1989 Jun; 83(6):2003-7. PubMed ID: 2542379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose mithramycin exerts its anticancer effect via the p53 signaling pathway and synergizes with nutlin-3 in gynecologic cancers.
    Ohgami T; Kato K; Kobayashi H; Sonoda K; Inoue T; Yamaguchi S; Yoneda T; Wake N
    Cancer Sci; 2010 Jun; 101(6):1387-95. PubMed ID: 20331637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of IL-3 on promoter usage, attenuation and antisense transcription of the c-myc oncogene in the IL-3-dependent Ba/F3 early pre-B cell line.
    Chang Y; Spicer DB; Sonenshein GE
    Oncogene; 1991 Nov; 6(11):1979-82. PubMed ID: 1682864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variable pause positions of RNA polymerase II lie proximal to the c-myc promoter irrespective of transcriptional activity.
    Wolf DA; Strobl LJ; Pullner A; Eick D
    Nucleic Acids Res; 1995 Sep; 23(17):3373-9. PubMed ID: 7567445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of RNA polymerase II transcription in human cell extracts by cisplatin DNA damage.
    Cullinane C; Mazur SJ; Essigmann JM; Phillips DR; Bohr VA
    Biochemistry; 1999 May; 38(19):6204-12. PubMed ID: 10320349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The block to transcriptional elongation within the human c-myc gene is determined in the promoter-proximal region.
    Krumm A; Meulia T; Brunvand M; Groudine M
    Genes Dev; 1992 Nov; 6(11):2201-13. PubMed ID: 1427080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra- and intermolecular triplex DNA formation in the murine c-myb proto-oncogene promoter are inhibited by mithramycin.
    Vigneswaran N; Thayaparan J; Knops J; Trent J; Potaman V; Miller DM; Zacharias W
    Biol Chem; 2001 Feb; 382(2):329-42. PubMed ID: 11308031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accurate, TATA box-dependent polymerase III transcription from promoters of the c-myc gene in injected Xenopus oocytes.
    Bentley DL; Brown WL; Groudine M
    Genes Dev; 1989 Aug; 3(8):1179-89. PubMed ID: 2792759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcription elongation in the human c-myc gene is governed by overall transcription initiation levels in Xenopus oocytes.
    Spencer CA; Kilvert MA
    Mol Cell Biol; 1993 Feb; 13(2):1296-305. PubMed ID: 8423795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of premature termination in c-myc during transcription by RNA polymerase II in a HeLa nuclear extract.
    London L; Keene RG; Landick R
    Mol Cell Biol; 1991 Sep; 11(9):4599-615. PubMed ID: 1715021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.